Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study

Urology. 1990 Jun;35(6):552-8. doi: 10.1016/0090-4295(90)80116-5.

Abstract

Pentosan polysulfate sodium (PPS) was compared with placebo for the symptomatic therapy of interstitial cystitis in a double-blind, multicenter study. A total of 110 patients were enrolled and treated for three months. In this study, overall improvement of greater than 25 percent was reported by 28 percent of the PPS-treated patients and by 13 percent of the placebo-treated patients (p = 0.03). The investigators' overall evaluation provided similar results, 26 percent vs 11 percent in favor of PPS (p = 0.04). Improvement in pain and pressure to urinate also favored PPS over placebo and approached statistical significance (p = 0.07 and 0.08). The incidence of adverse reactions was 6 percent in the PPS-treated group and 13 percent in the placebo-treated group. All adverse reactions were minor, and treatment was discontinued by 1 patient in the PPS group and 2 in the placebo group. In this study, PPS was found to be significantly more effective than, and equally as safe as, placebo.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Multicenter Study

MeSH terms

  • Adult
  • Cystitis / drug therapy*
  • Cystitis / urine
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Multicenter Studies as Topic
  • Pain Measurement / drug effects
  • Pentosan Sulfuric Polyester / adverse effects
  • Pentosan Sulfuric Polyester / therapeutic use*
  • Polysaccharides / therapeutic use*

Substances

  • Polysaccharides
  • Pentosan Sulfuric Polyester